Advances in Colorectal Cancer
New drugs show promise, but more research needs to be done.
Colorectal cancer is the third most common cancer in the U.S. and the second most common cancer killer. But in the last few years, researchers have made new discoveries that may dramatically improve the prognosis for people living with the disease.
"This is a very exciting moment in the treatment of colorectal cancer," says Meg Mooney, MD, a senior investigator at the Clinical Investigational Branch at the National Cancer Institute. "For a long time, we just weren't able to do much in terms of making a real difference in a patient's care. But now we have new medications that really show improvement in the survival of people with the disease."
Admittedly, there's no miracle cure out there yet and a great deal of research still needs to be done. But these new discoveries are a cause for real hope.
For decades, Mooney says, the main drug treatment for colorectal cancer was limited to two drugs, Adrucil and Wellcovorin. But beginning in 2000, things began to change.
In that year, the FDA approved the chemotherapy drug Camptosar for first-line use in people with metastatic colorectal cancer -- cancer that has spread outside the colon and into other parts of the body. Studies show that people using a combination of Camptosar with other drugs lived longer than those using traditional chemotherapy.
Then more recently, a study by the National Cancer Institute showed that another chemotherapy drug, Eloxatin, was more effective than Camptosar when both were combined with the traditional chemotherapy drugs.
"After relying on the same two drugs for years, all of the sudden we have two more drugs that can help people with metastatic colorectal cancer live longer," Mooney tells WebMD. "In the last four years, a lot has happened."
Two news colorectal cancer drugs -- Avastin and Erbitux -- were approved by the FDA in February.
Antiangiogenesis, at Last?
The promising trials of the drug Avastin have been one of the biggest stories in the treatment of colorectal cancer. A recently published study of people with metastatic colorectal cancer found that those who received Avastin in addition to standard chemotherapy lived about four months longer than people who just received standard chemotherapy. This might not seem like a big improvement, but the study involved people with advanced colorectal cancer who often don't respond very well to treatment.